Show simple item record

dc.contributor.authorGao, Qingsong
dc.contributor.authorLiang, Wen-Wei
dc.contributor.authorFoltz, Steven M
dc.contributor.authorMutharasu, Gnanavel
dc.contributor.authorJayasinghe, Reyka G
dc.contributor.authorCao, Song
dc.contributor.authorLiao, Wen-Wei
dc.contributor.authorReynolds, Sheila M
dc.contributor.authorWyczalkowski, Matthew A
dc.contributor.authorYao, Lijun
dc.contributor.authorYu, Lihua
dc.contributor.authorSun, Sam Q
dc.contributor.authorFusion Analysis Working Group
dc.contributor.authorCancer Genome Atlas Research Network
dc.contributor.authorChen, Ken
dc.contributor.authorLazar, Alexander J
dc.contributor.authorFields, Ryan C
dc.contributor.authorWendl, Michael C
dc.contributor.authorVan Tine, Brian A
dc.contributor.authorVij, Ravi
dc.contributor.authorChen, Feng
dc.contributor.authorNykter, Matti
dc.contributor.authorShmulevich, Ilya
dc.contributor.authorDing, Li
dc.date.accessioned2018-10-10T05:18:12Z
dc.date.available2018-10-10T05:18:12Z
dc.date.issued2018-04-03
dc.identifier.issn2211-1247
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/283402
dc.description.abstractGene fusions represent an important class of somatic alterations in cancer. We systematically investigated fusions in 9,624 tumors across 33 cancer types using multiple fusion calling tools. We identified a total of 25,664 fusions, with a 63% validation rate. Integration of gene expression, copy number, and fusion annotation data revealed that fusions involving oncogenes tend to exhibit increased expression, whereas fusions involving tumor suppressors have the opposite effect. For fusions involving kinases, we found 1,275 with an intact kinase domain, the proportion of which varied significantly across cancer types. Our study suggests that fusions drive the development of 16.5% of cancer cases and function as the sole driver in more than 1% of them. Finally, we identified druggable fusions involving genes such as TMPRSS2, RET, FGFR3, ALK, and ESR1 in 6.0% of cases, and we predicted immunogenic peptides, suggesting that fusions may provide leads for targeted drug and immune therapy.
dc.format.mediumPrint
dc.languageeng
dc.publisherElsevier BV
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectFusion Analysis Working Group
dc.subjectCancer Genome Atlas Research Network
dc.titleDriver Fusions and Their Implications in the Development and Treatment of Human Cancers.
dc.typeArticle
prism.endingPage238.e3
prism.issueIdentifier1
prism.publicationDate2018
prism.publicationNameCell Rep
prism.startingPage227
prism.volume23
dc.identifier.doi10.17863/CAM.30770
pubs.declined2018-06-06T10:18:34.344+0100
dcterms.dateAccepted2018-03-13
rioxxterms.versionofrecord10.1016/j.celrep.2018.03.050
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2018-04
dc.identifier.eissn2211-1247
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International